Treatment outcome of docetaxel, capecitabine and cisplatin regimen for patients with refractory and relapsed nasopharyngeal carcinoma who failed previous platinum-based chemotherapy
| Autor: | Xiao Xiao Wang, Qing Qing Cai, Yan Gao, Qi Chun Cai, Bing Bai, Hui Qiang Huang |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male Oncology Herpesvirus 4 Human medicine.medical_specialty Adolescent medicine.medical_treatment Docetaxel Deoxycytidine Disease-Free Survival Capecitabine Young Adult Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Carcinoma Humans Pharmacology (medical) Survival rate Aged Pharmacology Cisplatin Chemotherapy Nasopharyngeal Carcinoma business.industry Remission Induction Nasopharyngeal Neoplasms General Medicine Middle Aged medicine.disease Survival Rate Regimen Treatment Outcome Nasopharyngeal carcinoma DNA Viral Multivariate Analysis Female Taxoids Fluorouracil Neoplasm Recurrence Local business Follow-Up Studies medicine.drug |
| Zdroj: | Expert Opinion on Pharmacotherapy. 15:163-171 |
| ISSN: | 1744-7666 1465-6566 |
| DOI: | 10.1517/14656566.2014.866652 |
| Popis: | Although cisplatin combined with 5-fluorouracil is a common first-line regimen for advanced nasopharyngeal carcinoma (NPC), there are no standard regimens for refractory or relapsed patients. A study of DXD regimen [cisplatin (D), capecitabine (X) and docetaxel (D)] was conducted to evaluate the efficacy and toxicity for patients with refractory or relapsed NPC.The regimen was administered as follows: 50 mg/m(2) docetaxel and 50 mg/m(2) cisplatin on day 1 and 800 mg/m² capecitabine on days 1 - 14, repeated every 3 - 4 weeks.Thirty patients were enrolled. The overall response and complete remission rate was 46.4 and 21.4%. Median follow-up was 24 months; median overall survival (OS) and progression-free survival (PFS) were 14.0 and 8.0 months. Five-year OS and PFS rates were 14.8 and 13.3%, respectively. Four patients achieved long-term tumor-free survival (range, 53.8 - 125.3 months). Multivariate analysis demonstrated that Epstein-Barr virus DNA status (p = 0.003) and therapeutic effect (p0.001) were significant independent factors for OS and PFS. The main grade 3/4 toxicities included neutropenia (26.6%), anemia (13.3%) and thrombocytopenia (10.0%). There were no chemotherapy-related deaths.The DXD regimen appeared to be effective and well tolerated by patients with refractory or relapsed NPC. Further investigation is warranted. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|